-
公开(公告)号：US11931380B2
公开(公告)日：2024-03-19
申请号：US17230791
申请日：2021-04-14
IPC分类号： A61K35/17 , C07K2/00 , C07K16/30 , C07K16/40 , C12N5/0783 , C12N9/16 , C12N15/113 , A61K38/00 , A61K38/45
CPC分类号： A61K35/17 , C07K2/00 , C07K16/30 , C07K16/40 , C12N5/0638 , C12N9/16 , C12N15/1137 , A61K38/00 , A61K38/45 , C12N2310/11 , C12N2310/14 , C12N2310/531 , C12Y207/01107 , C12N2310/14 , C12N2310/531
摘要： The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DGK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.
-
公开(公告)号：US20240307445A1
公开(公告)日：2024-09-19
申请号：US18590493
申请日：2024-02-28
IPC分类号： A61K35/17 , A61K38/00 , A61K38/45 , C07K2/00 , C07K16/30 , C07K16/40 , C12N5/0783 , C12N9/16 , C12N15/113
CPC分类号： A61K35/17 , C07K2/00 , C07K16/30 , C07K16/40 , C12N5/0638 , C12N9/16 , C12N15/1137 , A61K38/00 , A61K38/45 , C12N2310/11 , C12N2310/14 , C12N2310/531 , C12Y207/01107
摘要： The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DOK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DOK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.
-
公开(公告)号：US20240117392A1
公开(公告)日：2024-04-11
申请号：US18274757
申请日：2022-02-09
IPC分类号： C12P7/6458 , C12N1/20 , C12N9/10 , C12N9/12 , C12N9/16
CPC分类号： C12P7/6458 , C12N1/205 , C12N9/1029 , C12N9/1205 , C12N9/16 , C12N2500/05 , C12N2500/34 , C12N2500/35 , C12Y203/01015 , C12Y203/0102 , C12Y207/01107 , C12Y301/03004
摘要： The technology described herein is directed to engineered chemoautotrophic bacteria and methods of producing triacylglycerides. Also described herein are systems or bioreactors comprising said engineered bacteria.
-
公开(公告)号：US20130137140A1
公开(公告)日：2013-05-30
申请号：US13704973
申请日：2011-06-15
CPC分类号： C12N15/81 , C12N9/1205 , C12N9/16 , C12N15/8257 , C12P21/00 , C12P21/02 , C12Y207/01107 , C12Y301/03002
摘要： The present application relates to the field of protein expression technologies. More specifically, it is demonstrated that cells with increased levels of phosphatidic acid, which can be achieved through either or both of phosphatidic acid inhibition and diacylglycerol kinase overexpression, display increased membrane formation from which increased levels of proteins can be recovered.
摘要翻译： 本申请涉及蛋白质表达技术领域。 更具体地说，证明可以通过磷脂酸抑制和二酰基甘油激酶过表达中的任一种或两者实现的具有增加的磷脂酸水平的细胞显示增加的膜形成，从中可以回收增加的蛋白质水平。
-
公开(公告)号：US20230250404A1
公开(公告)日：2023-08-10
申请号：US18176500
申请日：2023-03-01
申请人： UNIVERSITE DE STRASBOURG , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
发明人： HERVÉ MOINE , RICARDOS TABET
CPC分类号： C12N9/1205 , C12Y207/01107 , C12N15/86 , A61P43/00 , C12N2750/14143
摘要： The present invention relates to a nucleic acid coding for a human DGKk protein lacking a functional Proline Rich Region and/or a functional EPAPE repeated Region, and to its use in the treatment of fragile X syndrome in a patient in needs thereof.
-
公开(公告)号：US09937205B2
公开(公告)日：2018-04-10
申请号：US14425452
申请日：2013-09-04
IPC分类号： A61K35/14 , A61K35/17 , C12N15/113 , C12N5/0783 , C07K16/30 , C07K2/00 , C07K16/40 , C12N9/16 , A61K38/45 , A61K38/00
CPC分类号： A61K35/17 , A61K38/00 , A61K38/45 , C07K2/00 , C07K16/30 , C07K16/40 , C12N5/0638 , C12N9/16 , C12N15/1137 , C12N2310/11 , C12N2310/14 , C12N2310/531 , C12Y207/01107
摘要： The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DGK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.
-
7.发明申请公开(公告)号：US20150224142A1
公开(公告)日：2015-08-13
申请号：US14425452
申请日：2013-09-04
IPC分类号： A61K35/17 , C12N9/16 , C07K2/00 , C12N15/113 , C07K16/40
CPC分类号： A61K35/17 , A61K38/00 , A61K38/45 , C07K2/00 , C07K16/30 , C07K16/40 , C12N5/0638 , C12N9/16 , C12N15/1137 , C12N2310/11 , C12N2310/14 , C12N2310/531 , C12Y207/01107
摘要： The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DGK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.
摘要翻译： 本发明提供用于抑制细胞中一种或多种二酰基甘油激酶（DGK）同种型的组合物和方法，以增强细胞的溶细胞活性。 在一个实施方案中，细胞可以用于过继性T细胞转移。 例如，在一些实施方案中，修饰细胞以表达嵌合抗原受体（CAR）。 在过继性T细胞转移中使用的T细胞中DGK的抑制增加T细胞的溶细胞活性，因此可用于治疗各种病症，包括癌症，感染和免疫疾病。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.023 秒)
